AAAAAA

   
Results: 1-10 |
Results: 10
HYPOCHOLESTEROLEMIA IN THE ACUTE-PHASE OF INFLAMMATION DURING SEPSIS
Authors: BENTZ MH MAGNETTE J
Citation: Mh. Bentz et J. Magnette, HYPOCHOLESTEROLEMIA IN THE ACUTE-PHASE OF INFLAMMATION DURING SEPSIS, La Revue de medecine interne, 19(3), 1998, pp. 168-172
INTRAINDIVIDUAL VARIABILITY OF PARACETAMOL ABSORPTION KINETICS AFTER A SEMISOLID MEAL IN HEALTHY-VOLUNTEERS
Authors: PAINTAUD G THIBAULT P QUENEAU PE MAGNETTE J BERARD M RUMBACH L BECHTEL PR CARAYON P
Citation: G. Paintaud et al., INTRAINDIVIDUAL VARIABILITY OF PARACETAMOL ABSORPTION KINETICS AFTER A SEMISOLID MEAL IN HEALTHY-VOLUNTEERS, European Journal of Clinical Pharmacology, 53(5), 1998, pp. 355-359
INHIBITION OF CAFFEINE METABOLISM BY 5-METHOXYPSORALEN IN PATIENTS WITH PSORIASIS
Authors: BENDRISS EK BECHTEL Y BENDRISS A HUMBERT P PAINTAUD G MAGNETTE J AGACHE P BECHTEL PR
Citation: Ek. Bendriss et al., INHIBITION OF CAFFEINE METABOLISM BY 5-METHOXYPSORALEN IN PATIENTS WITH PSORIASIS, British journal of clinical pharmacology, 41(5), 1996, pp. 421-424
BIOAVAILABILITY AND TOLERANCE OF INDOMETH ACIN AS POLYMERIC NANOCAPSULES IN HUMANS
Authors: MABOUNDOU CW PAINTAUD G OTTIGNON Y MAGNETTE J BECHTEL Y FESSI H GOUCHET F CARAYON P BECHTEL P
Citation: Cw. Maboundou et al., BIOAVAILABILITY AND TOLERANCE OF INDOMETH ACIN AS POLYMERIC NANOCAPSULES IN HUMANS, Therapie, 51(1), 1996, pp. 88-89
A SINGLE-DOSE OF URSODIOL DOES NOT AFFECT CYCLOSPORINE ABSORPTION IN LIVER-TRANSPLANT PATIENTS
Authors: MABOUNDOU CW PAINTAUD G VANLEMMENS C MAGNETTE J BRESSONHADNI S MANTION G MIGUET JP BECHTEL PR
Citation: Cw. Maboundou et al., A SINGLE-DOSE OF URSODIOL DOES NOT AFFECT CYCLOSPORINE ABSORPTION IN LIVER-TRANSPLANT PATIENTS, European Journal of Clinical Pharmacology, 50(4), 1996, pp. 335-337
CINCHONINE PER-OS - EFFICIENT CIRCUMVENTION OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE
Authors: GENNE P DUCHAMP O SOLARY E MAGNETTE J BELON JP CHAUFFERT B
Citation: P. Genne et al., CINCHONINE PER-OS - EFFICIENT CIRCUMVENTION OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE, Anti-cancer drug design, 10(2), 1995, pp. 103-118
STABILITY OF DEBRISOQUINE (CYP2D6) PHENOTYPE IN LIVER-TRANSPLANT PATIENTS
Authors: BENDRISS A BECHTEL Y PAINTAUD G BENDRISS EK JOANNE C BRESSONHADNI S MAGNETTE J BECKER MC GILLET M MANTION G MIGUET JP BECHTEL PR
Citation: A. Bendriss et al., STABILITY OF DEBRISOQUINE (CYP2D6) PHENOTYPE IN LIVER-TRANSPLANT PATIENTS, Therapeutic drug monitoring, 17(2), 1995, pp. 113-119
PHARMACOKINETICS OF A MORE RELIABLE CHLORAMINOPHENE(R) FORMULATION
Authors: MABOUNDOU CW MAGNETTE J PAINTAUD G DUPOND JL FEST T NAJMAN A SOLARY E XICLUNA A SIRITO A CAHN JY
Citation: Cw. Maboundou et al., PHARMACOKINETICS OF A MORE RELIABLE CHLORAMINOPHENE(R) FORMULATION, Nouvelle revue francaise d'hematologie, 37(6), 1995, pp. 297-300
IS DEBRISOQUINE HYDROXYLATION MODIFIED DURING ACUTE VIRAL-HEPATITIS
Authors: JOANNE C PAINTAUD G BRESSONHADNI S MAGNETTE J BECKER MC MIGUET JP BECHTEL PR
Citation: C. Joanne et al., IS DEBRISOQUINE HYDROXYLATION MODIFIED DURING ACUTE VIRAL-HEPATITIS, Fundamental and clinical pharmacology, 8(1), 1994, pp. 76-79
A POPULATION AND FAMILY STUDY OF N-ACETYLTRANSFERASE USING CAFFEINE URINARY METABOLITES
Authors: BECHTEL YC BONAITIPELLIE C POISSON N MAGNETTE J BECHTEL PR
Citation: Yc. Bechtel et al., A POPULATION AND FAMILY STUDY OF N-ACETYLTRANSFERASE USING CAFFEINE URINARY METABOLITES, Clinical pharmacology and therapeutics, 54(2), 1993, pp. 134-141
Risultati: 1-10 |